Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China
- 10 June 2016
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 19 (11), 1056-1060
- https://doi.org/10.1080/13696998.2016.1194277
Abstract
Objectives: To evaluate the cost-effectiveness of 10 mg ilaprazole once-daily vs 20 mg omeprazole once-daily to treat newly-diagnosed duodenal ulcer patients in China. Methods: A decision tree model was constructed and the treatment impact was projected up to 1 year. The CYP2C19 polymorphism distribution in the Chinese population, the respective cure rates in the CYP2C19 genotype sub-groups, the impact of Duodenal Ulcer (DU) on utility value and drug-related side-effect data were obtained from the literature. The total costs of medications were calculated to estimate the treatment costs based on current drug retail prices in China. Expert surveys were conducted when published data were not available. Probabilistic sensitivity analysis was performed to gauge the robustness of the results. Results: Ilaprazole, when compared with omeprazole, achieved a better overall clinical efficacy. For the overall population, ilaprazole achieved an incremental cost effectiveness ratio (ICER) of ¥132 056 per QALY gained. This is less than the WHO recommended threshold of 3-times the average GDP per capita in China (2014). Furthermore, sub-group analysis showed that ilaprazole is cost-effective in every province in CYP2C19 hetEM patients and in the most developed provinces in CYP2C19 homEM patients. Probabilistic sensitivity analysis suggests that the results are robust with 97% probability that ilaprozole is considered cost-effective when a threshold of 3-times China’s average GDP per capita is considered. Limitation: This study didn’t have the data of ilaprazole combined with Hp eradication therapy. Caution should be taken when extrapolating these findings to DU patients with an Hp eradication therapy. Conclusions: The cost-effectiveness analysis results demonstrated that ilaprazole would be considered a cost-effective therapy, compared with omeprazole, in Chinese DU patients based on the efficacy projections in various CYP2C19 polymorphism types.Keywords
Funding Information
- Livzon Pharmaceutical Group Inc
This publication has 13 references indexed in Scilit:
- Efficacy of ilaprazole in the treatment of duodenal ulcers: A meta-analysisWorld Journal of Gastroenterology, 2014
- A comparison of the acid‐inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphismAlimentary Pharmacology & Therapeutics, 2012
- Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5Xenobiotica, 2011
- A New PPI, Ilaprazole Compared With Omeprazole in the Treatment of Duodenal UlcerJournal of Clinical Gastroenterology, 2011
- Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008Quality of Life Research, 2010
- Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcersThe Esophagus, 2009
- Proton pump inhibitors: an update of their clinical use and pharmacokineticsEuropean Journal of Clinical Pharmacology, 2008
- Peptic Ulcer Disease in a General Adult PopulationAmerican Journal of Epidemiology, 2006
- CYP2C19 Polymorphism and Proton Pump InhibitorsBasic & Clinical Pharmacology & Toxicology, 2004
- Generalized cost-effectiveness analysis for national-level priority-setting in the health sectorCost Effectiveness and Resource Allocation, 2003